Breaking News Instant updates and real-time market news.

EOLS

Evolus

$15.89

(0.00%)

07:08
11/04/19
11/04
07:08
11/04/19
07:08

Evolus reports Q3 EPS (98c), consensus ($1.13)

Reports Q3 revenue $13.2M, consensus $4.05M. "This was an exceptional quarter for the company on many fronts, in the U.S. and internationally," said David Moatazedi, President and Chief Executive Officer. "In our first full quarter on the U.S. market, we reported $13.2 million in net revenue and Jeuveau captured the number three market position. We established a broad base of over 2,000 accounts ordering Jeuveau. During the third quarter, re-orders represented an increasing portion of our revenue with a steady increase of new accounts month-over-month. Internationally, we obtained approval for Nuceiva in the European Union giving us access to 31 countries across Europe and we look forward to commercial launch in 2020. Additionally, Nuceiva recently launched in Canada."

  • 04

    Nov

EOLS Evolus
$15.89

(0.00%)

07/11/19
WELS
07/11/19
NO CHANGE
WELS
Market right in seeing rebate news as risk to pharmaceuticals, says Wells Fargo
Most pharmaceuticals stocks are down today due to a number of factors, including reports that the Trump Administration is abandoning its plan to lower drug prices by eliminating or restricting pharmacy benefit manager rebating, Wells Fargo analyst David Maris tells investors in a research note. The analyst believes the market is correctly interpreting the move as a potential risk to drugmakers. The absence of a rebating fix "does not mean there will not be a plan to address drug prices, but perhaps a greater risk that the absence of a rebate fix will put additional pressure to come up with ways to actually lower prices in ways that could more greatly impact drug makers than the rebating fix would have," contends Maris. He points out that companies with large cash-pay components of their business, like Allergan (AGN), Establishment Labs (ESTA), Evolus (EOLS), GlaxoSmithKline (GSK), Perrigo (PRGO), Revance (RVNC) and Sientra (SIEN), do not seem to be under as much pressure today as some of their more generic or pharma-concentrated peers. Maris says his Outperform ratings on Allergan, Establishment and Sientra are in part due to their cash-pay concentration
07/31/19
STFL
07/31/19
NO CHANGE
STFL
Buy
Physician survey bodes well for Evolus and Revance, says Stifel
Stifel analyst Annabel Samimy said her survey of 50+ physicians in late June lead her to now believe that new toxins could have penetrations that exceed her current market-share estimates. The survey bodes well for Evolus (EOLS) in the near-term and for both Evolus and Revance (RVNC) in the longer-term while also indicating that Allergan's (AGN) Botox franchise may be more vulnerable than previously thought, Samimy tells investors. She previously had Evolus' Jeuveau reaching a peak market share of 15% and Revance's DaxibotulinumtoxinA reaching 20% shares by 2027, but her new "base case" assumes that Jeuveau peaks at 20% share and Daxi peaks at 25%, noted Samimy, who took down her Botox market share forecast for 2027 to 50%. Samimy raised her price target on Evolus shares to $33 from $30 and keeps a $50 price target on Revance while maintaining Buy ratings on both stocks.
08/13/19
JMPS
08/13/19
NO CHANGE
Target $30
JMPS
Outperform
Evolus price target lowered to $30 from $35 at JMP Securities
JMP Securities analyst Donald Ellis lowered his price target on Evolus to $30 after its Q2 earnings miss and to reflect the updated share count for the stock in his valuation model. The analyst is keeping his Outperform rating however, noting that the company's launch of JEUVEAU on May 15 has exceeded expectations on several metrics, including "physician practices joining the JET trial" and patient satisfaction. Ellis maintains his expectation for JEUVEAU to achieve the management's target of a #2 position in the U.S. aesthetic toxin market.
09/05/19
MZHO
09/05/19
INITIATION
Target $30
MZHO
Buy
Evolus assumed with a Buy at Mizuho
Mizuho analyst Difei Yang assumed coverage of Evolus with an unchanged Buy rating and $30 price target. The company's "innovative" Jeuveau neurotoxin will capture significant share in the "attractive" neurotoxin market, Yang tells investors in a research note.

TODAY'S FREE FLY STORIES

AEIS

Advanced Energy

$69.48

2.17 (3.22%)

08:07
12/13/19
12/13
08:07
12/13/19
08:07
Conference/Events
Advanced Energy to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

BKNG

Booking Holdings

$1,948.89

22.44 (1.16%)

08:07
12/13/19
12/13
08:07
12/13/19
08:07
Recommendations
Booking Holdings analyst commentary  »

Booking Holdings named a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKYI

BIO-key

$0.57

-0.0305 (-5.08%)

08:05
12/13/19
12/13
08:05
12/13/19
08:05
Hot Stocks
Florida's Orange County Supervisor of Elections selects BIO-key solutions »

BIO-key Internationaly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$193.52

1.695 (0.88%)

08:05
12/13/19
12/13
08:05
12/13/19
08:05
Recommendations
Cigna analyst commentary  »

Cigna named a best idea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

COST

Costco

$297.50

2.28 (0.77%)

08:04
12/13/19
12/13
08:04
12/13/19
08:04
Recommendations
Costco analyst commentary  »

Costco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

EAST

Eastside Distilling

$2.91

-0.02 (-0.68%)

08:04
12/13/19
12/13
08:04
12/13/19
08:04
Hot Stocks
Eastside Distilling partners with Publix to offer Redneck Riviera Whiskey »

Eastside Distilling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNHI

CNH Industrial

$10.73

0.215 (2.04%)

08:04
12/13/19
12/13
08:04
12/13/19
08:04
Hot Stocks
AGXTEND acquires minority stake in Geoprospectors, terms not disclosed »

AGXTEND, CNH…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$57.52

0.62 (1.09%)

08:04
12/13/19
12/13
08:04
12/13/19
08:04
Hot Stocks
Rio Tinto receives aluminum certifications for several facilities »

Rio Tinto is now offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$73.75

0.93 (1.28%)

08:03
12/13/19
12/13
08:03
12/13/19
08:03
Recommendations
Blueprint Medicines analyst commentary  »

Blueprint Medicines named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHH

Choice Hotels

$101.43

1.32 (1.32%)

08:02
12/13/19
12/13
08:02
12/13/19
08:02
Hot Stocks
Choice Hotels raises quarterly dividend 5% to 22.5c from 21.5c per share »

Effective with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICPT

Intercept

$115.78

-3.55 (-2.97%)

08:02
12/13/19
12/13
08:02
12/13/19
08:02
Hot Stocks
Intercept submits MAA for OCA for treatment of fibrosis due to NASH »

Intercept Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

LLY

Eli Lilly

$121.69

0.83 (0.69%)

08:02
12/13/19
12/13
08:02
12/13/19
08:02
Hot Stocks
Eli Lilly, Boehringer Ingelheim provide update from EMPERIAL trials »

Boehringer Ingelheim and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 30

    Jan

ZNGA

Zynga

$6.20

0.07 (1.14%)

08:00
12/13/19
12/13
08:00
12/13/19
08:00
Recommendations
Zynga analyst commentary  »

Zynga named a best idea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTWO

Take-Two

$125.33

2.95 (2.41%)

08:00
12/13/19
12/13
08:00
12/13/19
08:00
Options
TakeTwo Interactive Software call buyer realizes 150% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

GPN

Global Payments

$175.07

0.43 (0.25%)

07:57
12/13/19
12/13
07:57
12/13/19
07:57
Recommendations
Global Payments analyst commentary  »

Global Payments named a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$58.52

-0.13 (-0.22%)

07:55
12/13/19
12/13
07:55
12/13/19
07:55
Conference/Events
Centene to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

AGCO

Agco

$78.09

1.47 (1.92%)

07:55
12/13/19
12/13
07:55
12/13/19
07:55
Conference/Events
Agco to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

EYES

Second Sight

$0.77

-0.0202 (-2.56%)

07:53
12/13/19
12/13
07:53
12/13/19
07:53
Initiation
Second Sight initiated  »

Second Sight initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXAS

Exact Sciences

$85.39

0.23 (0.27%)

07:52
12/13/19
12/13
07:52
12/13/19
07:52
Initiation
Exact Sciences initiated  »

Exact Sciences initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

07:51
12/13/19
12/13
07:51
12/13/19
07:51
Recommendations
Cigna analyst commentary  »

Cigna a Top pick and Best…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

TREE

LendingTree

$293.67

-13 (-4.24%)

07:51
12/13/19
12/13
07:51
12/13/19
07:51
Recommendations
LendingTree analyst commentary  »

LendingTree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$51.08

1.48 (2.98%)

, AMTD

TD Ameritrade

$53.47

1.71 (3.30%)

07:46
12/13/19
12/13
07:46
12/13/19
07:46
Upgrade
Charles Schwab, TD Ameritrade, E-Trade rating change  »

Charles Schwab upgraded…

SCHW

Charles Schwab

$51.08

1.48 (2.98%)

AMTD

TD Ameritrade

$53.47

1.71 (3.30%)

ETFC

E-Trade

$46.01

1.08 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 26

    Feb

07:45
12/13/19
12/13
07:45
12/13/19
07:45
General news
Treasury Market Outlook: it's rally time in equities »

Treasury Market Outlook:…

HIIQ

Health Insurance Innovations

$19.44

1.09 (5.94%)

, EHTH

eHealth

$93.74

0.89 (0.96%)

07:44
12/13/19
12/13
07:44
12/13/19
07:44
Recommendations
Health Insurance Innovations, eHealth analyst commentary  »

Health Insurance…

HIIQ

Health Insurance Innovations

$19.44

1.09 (5.94%)

EHTH

eHealth

$93.74

0.89 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$63.96

1.565 (2.51%)

07:43
12/13/19
12/13
07:43
12/13/19
07:43
Upgrade
Bristol-Myers rating change  »

Bristol-Myers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.